Eu2P: HOW DOES IT WORK?


MAKE UP YOUR MIND ABOUT THE LEADING TRAINING PROGRAMME


IN PHARMACOVIGILANCE AND PHARMACOEPIDEMIOLOGY!


PROJECT HISTORY [2009-2016]

The Eu2P training programme has been created thanks to the financial support of the Innovative Medicines Initiative (IMI), a joint undertaking between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA):

IMI logo       EU logo efpia logo

Work Packages

  • WP1: Programme and course coordination
    Co-led by Université de Bordeaux and Roche

  • WP2: Project management and communication
    Co-led by Université de Bordeaux and AstraZeneca
  • WP3: Common training and communication tools
    Co-led by Université de Bordeaux and Bayer Healthcare
  • WP4: Benefit assessment of medicines
    Co-led by Fundació Institut Català de Farmacologia, Barcelona and Roche
  • WP5: Regulatory aspects in the evaluation of medicines
    Co-led by University of Hertfordshire and GlaxoSmithKline
  • WP6: Medicines risk identification and quantification
    Co-led by Erasmus Universitair Medisch Centrum, Rotterdam and Sanofi-Aventis (and then Lundbeck)
  • WP7: Medicines benefit-risk assessment and management
    Co-led by Universiteit Utrecht and Roche
  • WP8: Medicines and public health
    Co-led by Fundació Institut Català de Farmacologia, Barcelona and Amgen
  • WP9: Medicines Risk communication
    Co-led by Université de Bordeaux and Lilly

 

Public-Private Partnership Consortium

Universities, Research Organisations, Public Bodies & Non-Profit

  • Université de Bordeaux
    IMI Funding Managing Entity
    Co-leader of WP1, WP2, WP3 and WP9 (with Università degli Studi di Verona)
  • Fundació Institut Català de Farmacologia, Universitat Autònoma de Barcelona
    Co-leader of WP4, WP8
  • University of Hertfordshire
    Co-leader of WP5
  • Erasmus Universitair Medisch Centrum, Rotterdam
    Co-leader of WP6
  • Universiteit Utrecht
    Co-leader of WP7
  • Università degli Studi di Verona
    Co-leader of WP9 (with Université de Bordeaux)
  • Karolinska Institutet
    Active collaboration in WP8



  • European Medicines Agency
    Active collaboration in WP5
  • Agence Nationale de Sécurité du Médicament
    Active collaboration in WP9

EFPIA

  • Roche
    IMI Project Coordinator
    Co-leader of WP1, WP4, and WP7.
    Active collaboration in WP2, WP6 and WP8
  • AstraZeneca
    Co-leader of WP2.
    Active collaboration in WP9
  • Bayer Healthcare
    Co-leader of WP3.
    Active collaboration in WP1 and WP2
  • GlaxoSmithKline
    Co-leader of WP5
  • Sanofi
    Co-leader of WP6
  • AMGEN
    Co-leader of WP8.
    Active collaboration in WP4
  • Lilly
    Co-leader of WP9
  • Lundbeck
    Active collaboration in WP5 and WP7
  • Novartis
    Active collaboration in WP5
  • Orion Pharma
    Active collaboration in WP5
  • UCB
    Active collaboration in WP6
  • Almirall
    Active collaboration in WP7
  • Janssen
    Active collaboration in WP7
  • Boehringer Ingelheim
  • Novo Nordisk

: Members of the Steering Committee group.

 


Confused? Read the FAQs...

NEED TO TALK TO US?

+33 5 47 30 42 69

Monday-Friday / 9.00am-6.00pm CET

 

Supported By

IMI logo EU logo efpia logo

Created By

Eu2P Partners